Nebulized Nasal Steroids

NCT ID: NCT07270302

Last Updated: 2025-12-08

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-31
• Study Completion Date: 2026-05-31

Brief Summary

The goal of the proposed project is to assess the efficacy, safety, and patient experience of budesonide administered via the NasoNeb system for medical management of CRS. The authors propose a randomized controlled trial of nebulized budesonide via the NasoNeb compared against budesonide lavage.

Detailed Description

Chronic rhinosinusitis is primarily an inflammatory disorder affecting up to 1 in 8 individuals and causing economic burden of greater than 13 billion USD. The NasoNeb is FDA approved for the nasal administration of medications; however, it has been scarcely studied in the existing literature. Many patients are intolerant of or non-compliant with other modalities of nasal steroid administration, and the NasoNeb represents a potential new treatment method for these patients.

Participants will be provided with either a NasoNeb machine or NeilMed lavage bottle, and a prescription for a 42-day supply of 0.5 mg budesonide packets, to be used twice daily. For the NasoNeb, each dose will be dissolved in 10 mL saline with 5 mL nebulized solution being applied to each nasal cavity. This dose was chosen given the historical evidence of efficacy of budesonide 0.5mg daily application via saline lavage.

For the lavage, each budesonide dose will be dissolved in 240 mL saline. Participants will be shown proper use of the NasoNeb machine or lavage bottle at the time of enrollment and be given written instructions with links to video tutorials.

Conditions

Chronic Rhinosinusitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

nebulizer group

Subjects in the nebulizer group will be prescribed a 42-day supply of 0.5 mg budesonide packets, to be used twice daily without any concomitant saline lavage.

Group Type: EXPERIMENTAL

nebulized budesonide via NasoNeb

Intervention Type: COMBINATION_PRODUCT

For the nebulization group, each dose will be dissolved in 10 mL saline with 5 mL nebulized solution being applied to each nasal cavity.

Device: NasoNeb

budesonide lavage group

Subjects in the budesonide lavage group will be prescribed 42-day supply of 0.5 mg budesonide packets to be administered via 240 mL twice daily nasal saline lavage.

Group Type: ACTIVE_COMPARATOR

budesonide lavage via NeilMed

Intervention Type: COMBINATION_PRODUCT

For the lavage group, each dose will be dissolved in 240 mL saline and 120 mL of the solution will be administered to each nasal cavity.

Device: NeilMed

Interventions

nebulized budesonide via NasoNeb

For the nebulization group, each dose will be dissolved in 10 mL saline with 5 mL nebulized solution being applied to each nasal cavity.

Device: NasoNeb

Intervention Type: COMBINATION_PRODUCT

budesonide lavage via NeilMed

For the lavage group, each dose will be dissolved in 240 mL saline and 120 mL of the solution will be administered to each nasal cavity.

Device: NeilMed

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

• Age 18 or older that meet diagnostic criteria for CRS with or without polyposis as documented by their recruiting physician.
• Diagnostic criteria for CRS will be defined according to EPOS criteria of >12 weeks of 2 of the following subjective symptoms: nasal blockage or obstruction, rhinorrhea, hyposmia, or facial pain/pressure AND objective evidence of CRS on either nasal endoscopy or CT scan

Exclusion Criteria

• Patients who have previously undergone sinus surgery
• Severe polyposis; defined as Lund Kennedy endoscopy score greater than 1
• Patients who are currently using or who have previously used biologic medications for their nasal polyps. These medications include: dupilumab, omalizumab, mepolizumab, tezepelumab, or depemokimab
• Inability to complete surveys in English
• known comorbid mucociliary disease
• known adrenal disease or other HPA dysfunction
• patients taking oral corticosteroids for other medical conditions
• oral antibiotic administration within 2 weeks of study participation
• a baseline SNOT-22 score less than 9, due to inability to achieve the MCID

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nyssa Farrell, MD

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Nyssa Fox Farrell

St Louis, Missouri, United States

Countries

United States

Central Contacts

Nyssa Farrell, MD

Role: CONTACT

nyssa.farrell@wustl.edu

314-362-7509

Sara Kukuljan

Role: CONTACT

kukuljas@wustl.edu

314-362-7563

References

Tait S, Kallogjeri D, Suko J, Kukuljan S, Schneider J, Piccirillo JF. Effect of Budesonide Added to Large-Volume, Low-pressure Saline Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2018 Jul 1;144(7):605-612. doi: 10.1001/jamaoto.2018.0667.

Reference Type: BACKGROUND

PMID: 29879268 (View on PubMed)

Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, Poetker DM, Soler Z, Welch KC, Wise SK, Adappa N, Alt JA, Anselmo-Lima WT, Bachert C, Baroody FM, Batra PS, Bernal-Sprekelsen M, Beswick D, Bhattacharyya N, Chandra RK, Chang EH, Chiu A, Chowdhury N, Citardi MJ, Cohen NA, Conley DB, DelGaudio J, Desrosiers M, Douglas R, Eloy JA, Fokkens WJ, Gray ST, Gudis DA, Hamilos DL, Han JK, Harvey R, Hellings P, Holbrook EH, Hopkins C, Hwang P, Javer AR, Jiang RS, Kennedy D, Kern R, Laidlaw T, Lal D, Lane A, Lee HM, Lee JT, Levy JM, Lin SY, Lund V, McMains KC, Metson R, Mullol J, Naclerio R, Oakley G, Otori N, Palmer JN, Parikh SR, Passali D, Patel Z, Peters A, Philpott C, Psaltis AJ, Ramakrishnan VR, Ramanathan M Jr, Roh HJ, Rudmik L, Sacks R, Schlosser RJ, Sedaghat AR, Senior BA, Sindwani R, Smith K, Snidvongs K, Stewart M, Suh JD, Tan BK, Turner JH, van Drunen CM, Voegels R, Wang Y, Woodworth BA, Wormald PJ, Wright ED, Yan C, Zhang L, Zhou B. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021 Mar;11(3):213-739. doi: 10.1002/alr.22741.

Reference Type: BACKGROUND

PMID: 33236525 (View on PubMed)

Rudmik L. Economics of Chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2017 Apr;17(4):20. doi: 10.1007/s11882-017-0690-5.

Reference Type: BACKGROUND

PMID: 28337570 (View on PubMed)

Chung SD, Hung SH, Lin HC, Lin CC. Health care service utilization among patients with chronic rhinosinusitis: a population-based study. Laryngoscope. 2014 Jun;124(6):1285-9. doi: 10.1002/lary.24500. Epub 2013 Dec 10.

Reference Type: BACKGROUND

PMID: 24338913 (View on PubMed)

Bhattacharyya N. Contemporary assessment of the disease burden of sinusitis. Allergy Rhinol (Providence). 2010 Jan 1;1(1):8. doi: 10.2500/ajra.2009.23.3355. No abstract available.

Reference Type: BACKGROUND

PMID: 28569228 (View on PubMed)

Bhattacharyya N, Orlandi RR, Grebner J, Martinson M. Cost burden of chronic rhinosinusitis: a claims-based study. Otolaryngol Head Neck Surg. 2011 Mar;144(3):440-5. doi: 10.1177/0194599810391852. Epub 2011 Feb 3.

Reference Type: BACKGROUND

PMID: 21493210 (View on PubMed)

Phillips KM, Hoehle LP, Bergmark RW, Caradonna DS, Gray ST, Sedaghat AR. Acute Exacerbations Mediate Quality of Life Impairment in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2017 Mar-Apr;5(2):422-426. doi: 10.1016/j.jaip.2016.09.015. Epub 2016 Nov 7.

Reference Type: BACKGROUND

PMID: 27839750 (View on PubMed)

Phillips KM, Hoehle LP, Caradonna DS, Gray ST, Sedaghat AR. Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis. Clin Otolaryngol. 2018 Oct;43(5):1328-1334. doi: 10.1111/coa.13177. Epub 2018 Jul 26.

Reference Type: BACKGROUND

PMID: 29953729 (View on PubMed)

Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, Grammer LC, Welch KC, Smith SS, Conley DB, Kern RC, Schleimer RP, Kato A. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2812-2820.e3. doi: 10.1016/j.jaip.2019.05.009. Epub 2019 May 22.

Reference Type: BACKGROUND

PMID: 31128376 (View on PubMed)

Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011993. doi: 10.1002/14651858.CD011993.pub2.

Reference Type: BACKGROUND

PMID: 27115215 (View on PubMed)

Joe SA, Thambi R, Huang J. A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008 Sep;139(3):340-7. doi: 10.1016/j.otohns.2008.05.628.

Reference Type: BACKGROUND

PMID: 18722209 (View on PubMed)

Fernandes AM, Valera FC, Anselmo-Lima WT. Mechanism of action of glucocorticoids in nasal polyposis. Braz J Otorhinolaryngol. 2008 Mar-Apr;74(2):279-83. doi: 10.1016/s1808-8694(15)31101-0.

Reference Type: BACKGROUND

PMID: 18568209 (View on PubMed)

Lee SH. Mechanisms of Glucocorticoid Action in Chronic Rhinosinusitis. Allergy Asthma Immunol Res. 2015 Nov;7(6):534-7. doi: 10.4168/aair.2015.7.6.534. Epub 2015 May 20.

Reference Type: BACKGROUND

PMID: 26333699 (View on PubMed)

Mastruzzo C, Greco LR, Nakano K, Nakano A, Palermo F, Pistorio MP, Salinaro ET, Jordana M, Dolovich J, Crimi DN, Vancheri C. Impact of intranasal budesonide on immune inflammatory responses and epithelial remodeling in chronic upper airway inflammation. J Allergy Clin Immunol. 2003 Jul;112(1):37-44. doi: 10.1067/mai.2003.1586.

Reference Type: BACKGROUND

PMID: 12847477 (View on PubMed)

Manji J, Singh G, Okpaleke C, Dadgostar A, Al-Asousi F, Amanian A, Macias-Valle L, Finkelstein A, Tacey M, Thamboo A, Javer A. Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017 May;7(5):488-493. doi: 10.1002/alr.21910. Epub 2017 Feb 2.

Reference Type: BACKGROUND

PMID: 28151588 (View on PubMed)

Palmer JN, Jacobson KW, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018 Jun 1;8(8):869-76. doi: 10.1002/alr.22141. Online ahead of print.

Reference Type: BACKGROUND

PMID: 29856520 (View on PubMed)

Thamboo A, Manji J, Szeitz A, Santos RD, Hathorn I, Gan EC, Alsaleh S, Javer AR. The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol. 2014 May;4(5):397-402. doi: 10.1002/alr.21280. Epub 2014 Jan 21.

Reference Type: BACKGROUND

PMID: 24449682 (View on PubMed)

Harvey RJ, Snidvongs K, Kalish LH, Oakley GM, Sacks R. Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol. 2018 Apr;8(4):461-470. doi: 10.1002/alr.22093. Epub 2018 Feb 2.

Reference Type: BACKGROUND

PMID: 29394004 (View on PubMed)

Yoo F, Ference EH, Kuan EC, Lee JT, Wang MB, Suh JD. Evaluation of patient nasal saline irrigation practices following endoscopic sinus surgery. Int Forum Allergy Rhinol. 2018 Jan;8(1):32-40. doi: 10.1002/alr.22034. Epub 2017 Oct 30.

Reference Type: BACKGROUND

PMID: 29083529 (View on PubMed)

Fox MG, Cass LM, Sykes KJ, Cummings EL, Fassas SN, Nallani R, Smith JB, Chiu AG, Villwock JA. Factors affecting adherence to intranasal treatment for allergic rhinitis: A qualitative study. Laryngoscope Investig Otolaryngol. 2022 Nov 29;8(1):40-45. doi: 10.1002/lio2.986. eCollection 2023 Feb.

Reference Type: BACKGROUND

PMID: 36846400 (View on PubMed)

Kovacs AJ, Adappa ND, Kuan EC. Exhalation Delivery Systems for Application of Intranasal Corticosteroids. Ear Nose Throat J. 2021 Jun;100(5):309-313. doi: 10.1177/0145561320980194. Epub 2020 Dec 11.

Reference Type: BACKGROUND

PMID: 33305974 (View on PubMed)

Waniewska-Leczycka M, Cieslik T, Kowalik K, Sierdzinski J, Zagor MP. Comparison of Intranasal Steroid Application Using Nasal Saline Irrigation and a Mucosal Atomization Device to Treat Chronic Rhinosinusitis. J Aerosol Med Pulm Drug Deliv. 2021 Sep;34(5):311-321. doi: 10.1089/jamp.2020.1644. Epub 2021 Apr 13.

Reference Type: BACKGROUND

PMID: 33848434 (View on PubMed)

Harvey RJ, Goddard JC, Wise SK, Schlosser RJ. Effects of endoscopic sinus surgery and delivery device on cadaver sinus irrigation. Otolaryngol Head Neck Surg. 2008 Jul;139(1):137-42. doi: 10.1016/j.otohns.2008.04.020.

Reference Type: BACKGROUND

PMID: 18585576 (View on PubMed)

Hosseini S, Wei X, Wilkins JV Jr, Fergusson CP, Mohammadi R, Vorona G, Golshahi L. In Vitro Measurement of Regional Nasal Drug Delivery with Flonase,(R) Flonase(R) Sensimist, and MAD Nasal in Anatomically Correct Nasal Airway Replicas of Pediatric and Adult Human Subjects. J Aerosol Med Pulm Drug Deliv. 2019 Dec;32(6):374-385. doi: 10.1089/jamp.2019.1523. Epub 2019 Aug 29.

Reference Type: BACKGROUND

PMID: 31464547 (View on PubMed)

Rotenberg BW. Comparison of Budesonide Delivery Via Nasal Spray and a Nasal Nebulizer to an In Vitro Adult Model. In: TP6. TP006 CLINICAL STUDIES OF ALLERGIC AIRWAY DISEASES, LUPUS, AND EOSINOPHILIC DISEASES.2021:A1338-A1338.

Reference Type: BACKGROUND

NasoNeb. Particle Size and AIrflow: Implications for Nasal and Paranasal SInus Delivery. https://cdn.shopify.com/s/files/1/0373/3943/1044/files/ParticleSizeAndAirflowInNasalDrugDelivery.pdf?v=1606769959. Accessed 1/2/2025.

Reference Type: BACKGROUND

Valentine R, Athanasiadis T, Thwin M, Singhal D, Weitzel EK, Wormald PJ. A prospective controlled trial of pulsed nasal nebulizer in maximally dissected cadavers. Am J Rhinol. 2008 Jul-Aug;22(4):390-4. doi: 10.2500/ajr.2008.22.3191.

Reference Type: BACKGROUND

PMID: 18702903 (View on PubMed)

Nasoneb Information for Physicians and Nurse Practitioners. Monaghan Medical Corporation. https://www.nasoneb.com/pages/physicians-nurse-practitioners. Accessed December 31, 2024.

Reference Type: BACKGROUND

Manes RP, Tong L, Batra PS. Prospective evaluation of aerosol delivery by a powered nasal nebulizer in the cadaver model. Int Forum Allergy Rhinol. 2011 Sep-Oct;1(5):366-71. doi: 10.1002/alr.20057. Epub 2011 May 9.

Reference Type: BACKGROUND

PMID: 22287468 (View on PubMed)

BW R. Comparison of Budesonide Delivery Via Nasal Spray and a Nasal Nebulizer to an In Vitro Adult Model. In: TP6. TP006 CLINICAL STUDIES OF ALLERGIC AIRWAY DISEASES, LUPUS, AND EOSINOPHILIC DISEASES.2021:A1338-A1338.

Reference Type: BACKGROUND

Brown K, Lane J, Silva MP, DeTineo M, Naclerio RM, Baroody FM. A pilot study of the effects of intranasal budesonide delivered by NasoNeb(R) on patients with perennial allergic rhinitis. Int Forum Allergy Rhinol. 2014 Jan;4(1):43-8. doi: 10.1002/alr.21239.

Reference Type: BACKGROUND

PMID: 24574125 (View on PubMed)

Megow A, Bouras G, Ooi EH, Vreugde S, Psaltis A, Wormald PJ. Double blind randomized controlled trial measuring the efficacy of nebulized steroid at half dose in comparison to high volume squeeze bottle steroid irrigation in management of patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2024 Aug;14(8):1375-1377. doi: 10.1002/alr.23336. Epub 2024 Mar 13.

Reference Type: BACKGROUND

PMID: 38477174 (View on PubMed)

Wang C, Lou H, Wang X, Wang Y, Fan E, Li Y, Wang H, Bachert C, Zhang L. Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2015 Apr;135(4):922-929.e6. doi: 10.1016/j.jaci.2014.10.018. Epub 2014 Dec 4.

Reference Type: BACKGROUND

PMID: 25483598 (View on PubMed)

Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2004 Jul;93(1):61-7. doi: 10.1016/S1081-1206(10)61448-2.

Reference Type: BACKGROUND

PMID: 15281473 (View on PubMed)

Smith KA, French G, Mechor B, Rudmik L. Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016 Mar;6(3):228-32. doi: 10.1002/alr.21700. Epub 2016 Jan 11.

Reference Type: BACKGROUND

PMID: 26750509 (View on PubMed)

Other Identifiers

202503084

Identifier Type: -

Identifier Source: org_study_id